From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 24 May

Jessica Amir
May 24, 2021

Weekly Wrap 21 May

Jessica Amir
May 21, 2021

Morning Bell 21 May

Sophia Mavridis
May 21, 2021

Morning Bell 20 May

Paulina Peters
May 20, 2021

Morning Bell 19 May

Jessica Amir
May 19, 2021

Morning Bell 18 May

Jessica Amir
May 18, 2021

Morning Bell 17 May

Jessica Amir
May 17, 2021

Weekly Wrap 14 May

Jessica Amir
May 14, 2021

Morning Bell 14 May

Sophia Mavridis
May 14, 2021

Morning Bell 13 May

Jessica Amir
May 13, 2021

Morning Bell 12 May

Paulina Peters
May 12, 2021